Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • Geneious
    Registered Vendor
    • Jul 2010
    • 22

    GENEWIZ and Biomatters announce strategic partnership

    South Plainfield, NJ and Auckland, New Zealand – 31 May, 2011 – GENEWIZ, Inc., the number one provider of DNA sequencing services in the United States, and Biomatters, creators of the leading DNA sequence analysis software Geneious Pro, have announced a strategic partnership that will provide an end-to-end solution for DNA sequencing from ordering, through sequencing or synthesis to analysis.

    The partnership will mean closer technical integration between the companies’ products and services. Samples sent to GENEWIZ for sequencing will be able to be directly downloaded into Geneious Pro for immediate visualization and analysis, eliminating the need for manual ordering and retrieval, particularly important for large volumes of sequences. Additionally, users will be able to submit in silico designed sequences or oligonucleotides for synthesis directly from Geneious Pro.

    GENEWIZ will provide customers with sequence results natively in the .geneious file format in addition to other standard formats. GENEWIZ customers can visualize their data in Geneious, giving them access to professional visualization and analysis tools, as well as best-in-class bioinformatics support for downstream analysis.

    “With a common mission to discover innovative scientific solutions, as well as to deliver the highest quality service, I am confident that our partnership with Biomatters will prove advantageous to customers’ research,” stated Dr. Shifang Zhang, Vice President of Corporate Development at GENEWIZ. “The additional analysis tools offered as well as the integration with Geneious will enable customers to further centralize sequencing data for easy access, analysis and management.”

    “GENEWIZ is the leader in their field, and by working together we are able to dramatically streamline the workflows of a huge number of researchers. With the large volumes of data scientists must manage these days a saving of minutes per sample soon adds up to a big contribution,” commented Candace Kinser, Biomatters CEO.

    “It’s all about making life easier for biologists, so that they can concentrate on the science,” Kinser added. GENEWIZ and Biomatters will also undertake joint marketing and referral campaigns. The two companies have complementary customer bases, with GENEWIZ customers requiring the types of analysis tools available in Geneious Pro and Biomatters customers requiring high-quality low-cost commercial laboratory services.

    Biomatters will add GENEWIZ-centric features in a future version of Geneious Pro, including the option to quickly ‘click and download’ sequence results from GENEWIZ’s online CLIMS directly into Geneious Pro, as well as ‘submit for synthesis’ services for gene and oligo synthesis services.

Latest Articles

Collapse

  • SEQadmin2
    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
    by SEQadmin2



    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
    ...
    Today, 11:10 AM
  • SEQadmin2
    Cancer Drug Resistance: The Lingering Barrier to Rising Survival
    by SEQadmin2



    Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

    There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
    Yesterday, 05:17 AM
  • GATTACAT
    Reply to Nine Things a Sample Prep Scientist Thinks About Before Sequencing
    by GATTACAT
    Love this - good data definitely starts from good input, and poor input can only give relatively poor data. I particularly like the mention of Nanodrop/absorbance based methods for quantification. It's such a toss up if you'll get an accurate reading or what amounts to a randomly generated number, and a lot of library/sequencing related issues can be traced back to poor quant.
    07-01-2026, 11:43 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, Today, 10:04 AM
0 responses
8 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, Yesterday, 10:08 AM
0 responses
7 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-07-2026, 11:05 AM
0 responses
9 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-02-2026, 11:08 AM
0 responses
31 views
0 reactions
Last Post SEQadmin2  
Working...